Roberts Pharmaceutical
Executive Summary
Has engaged investment banker Bear, Stearns & Co. "for the purpose of raising R&D funds for the completion of the development of several late stage pharmaceutical products." Drugs in the late stages of development include Amatine, for which an NDA is pending for urinary incontinence; Radinyl, in Phase III as an adjunct to radiation therapy; the opioid analgesic Dirame, in Phase III; and Somagard, an LHRH agent also in Phase III for the treatment of precocious puberty.